The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial

Stavropoulou, Evmorfia; Αrgyra, Eriphili; Zis, Panagiotis; Vadalouca, Athina; Siafaka, Ioanna

doi:10.1155/2014/853826

Cited by 35 publications

(54 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One RCT on the use of intravenous lidocaine in acute exacerbation was found . In this trial, a single dose of intravenous lidocaine (5 mg/kg over 60 min) was superior in reducing pain intensity compared to placebo during the first 24 h after the infusion.…”

Section: Section 2: Pharmacological Treatmentmentioning

confidence: 96%

European Academy of Neurology guideline on trigeminal neuralgia

Bendtsen

Zakrzewska

Abbott

et al. 2019

Euro J of Neurology

407

492

View full text Add to dashboard Cite

Background and purpose Trigeminal neuralgia (TN) is an extremely painful condition which can be difficult to diagnose and treat. In Europe, TN patients are managed by many different specialities. Therefore, there is a great need for comprehensive European guidelines for the management of TN. The European Academy of Neurology asked an expert panel to develop recommendations for a series of questions that are essential for daily clinical management of patients with TN. Methods A systematic review of the literature was performed and recommendations was developed based on GRADE, where feasible; if not, a good practice statement was given. Results The use of the most recent classification system is recommended, which diagnoses TN as primary TN, either classical or idiopathic depending on the degree of neurovascular contact, or as secondary TN caused by pathology other than neurovascular contact. Magnetic resonance imaging (MRI), using a combination of three high‐resolution sequences, should be performed as part of the work‐up in TN patients, because no clinical characteristics can exclude secondary TN. If MRI is not possible, trigeminal reflexes can be used. Neurovascular contact plays an important role in primary TN, but demonstration of a neurovascular contact should not be used to confirm the diagnosis of TN. Rather, it may help to decide if and when a patient should be referred for microvascular decompression. In acute exacerbations of pain, intravenous infusion of fosphenytoin or lidocaine can be used. For long‐term treatment, carbamazepine or oxcarbazepine are recommended as drugs of first choice. Lamotrigine, gabapentin, botulinum toxin type A, pregabalin, baclofen and phenytoin may be used either alone or as add‐on therapy. It is recommended that patients should be offered surgery if pain is not sufficiently controlled medically or if medical treatment is poorly tolerated. Microvascular decompression is recommended as first‐line surgery in patients with classical TN. No recommendation can be given for choice between any neuroablative treatments or between them and microvascular decompression in patients with idiopathic TN. Neuroablative treatments should be the preferred choice if MRI does not demonstrate any neurovascular contact. Treatment for patients with secondary TN should in general follow the same principles as for primary TN. In addition to medical and surgical management, it is recommended that patients are offered psychological and nursing support. Conclusions Compared with previous TN guidelines, there are important changes regarding diagnosis and imaging. These allow better characterization of patients and help in decision making regarding the planning of medical and surgical management. Recommendations on pharmacological and surgical management have been updated. There is a great need for future research on all aspects of TN, including pathophysiology and management.

show abstract

Section: Section 2: Pharmacological Treatmentmentioning

confidence: 96%

European Academy of Neurology guideline on trigeminal neuralgia

Bendtsen

Zakrzewska

Abbott

et al. 2019

Euro J of Neurology

407

492

View full text Add to dashboard Cite

show abstract

“…The latter can be purely neuropathic secondary to cranial neuropathies (ie, trigeminal neuralgia)34 or predominantly nociceptive secondary to temporomandibular disorders 35…”

Section: Phenomenology and Diagnostic Challengesmentioning

confidence: 99%

Depression and chronic pain in the elderly: links and management challenges

Zis

Daskalaki

Bountouni

et al. 2017

CIA

Self Cite

290

197

View full text Add to dashboard Cite

Aging is an inevitable process and represents the accumulation of bodily alterations over time. Depression and chronic pain are highly prevalent in elderly populations. It is estimated that 13% of the elderly population will suffer simultaneously from the two conditions. Accumulating evidence suggests than neuroinflammation plays a critical role in the pathogenesis of both depression and chronic pain. Apart from the common pathophysiological mechanisms, however, the two entities have several clinical links. Their management is challenging for the pain physician; however, both pharmacologic and nonpharmacologic approaches are available and can be used when the two conditions are comorbid in the elderly patients.

show abstract

“…There are some clinical reports that patients with trigeminal neuralgia, local and intravenous administration of lidocaine effectively attenuates of intensity of pain, including allodynia and hyperalgesia (Kanai et al, 2006;Han et al, 2008;Stavropoulou et al, 2014). Present study indicated that local injection of resveratrol may act in a manner similar to injection of a local anesthetic agent.…”

Section: Functional Significance Of Suppression Of Nociceptive Stimulmentioning

confidence: 55%